Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
Certain portions of our press release dated March 4, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 2.02. They are as follows:
|●||The 1st through 8th paragraphs relating to results of operations for 2018|
|●||The 9th paragraph relating to balance sheet items|
|●||The 13th paragraph relating to the conference call to be held on March 4, 2019|
|●||The unaudited consolidated statements of income and consolidated balance sheets|
Item 7.01 Regulation FD Disclosure
Certain portions of our press release dated March 4, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 7.01 and Regulation FD. They are as follows:
|●||The 10th paragraph relating plans for 2019 product launches|
|●||The 11th paragraph relating to 2019 guidance|
|●||The 15th paragraph relating to forward looking statements|
|●||The balance of such press release not otherwise incorporated by reference in Items 2.02 or 8.01|
Item 8.01 Other Events
The 12th paragraph of our press release dated March 4, 2019 relating to our cash dividend is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
99.1 Our press release dated March 4, 2019.
INTER PARFUMS INC Exhibit
EX-99.1 2 s116489_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 INTER PARFUMS,…
To view the full exhibit click
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.